Cited by 887Immunotherapy and Immune ResponsesAluminum toxicity and tolerance in plants and animalsImmune responses and vaccinations

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Towards an understanding of the adjuvant action of aluminium

Open access

Marrack, Philippa, McKee, Amy S., Munks, Michael W.·2009·Nature Reviews Immunology

DOI 10.1038/nri2510PMC PMC3147301

Open this paper in CoChat — free account

Abstract

The efficacy of vaccines depends on the presence of an adjuvant in conjunction with the antigen. Of these adjuvants, the ones that contain aluminium, which were first discovered empirically in 1926, are currently the most widely used. However, a detailed understanding of their mechanism of action has only started to be revealed. In this Timeline article, we briefly describe the initial discovery of aluminium adjuvants and discuss historically important advances. We also summarize recent progress in the field and discuss their implications and the remaining questions on how these adjuvants work.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nri2510

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.
Mosmann, T. R., Cherwinski, H. M., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,553
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658 · cited 1×
“Related reports have shown that other particulate materials, such as silica, asbestos and MSU crystals, also act through the NLRP3 inflammasome to produce IL-1&beta”
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Molecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Toll-like receptors control activation of adaptive immune responses
Schnare, M., Barton, G. M., Czopik, A. K., Takeda, K., Akira, S., & Medzhitov, R. M. (2001) · Nature Immunology · doi:10.1038/ni712 · Cited by 1,364
Disruption of the murine IL-4 gene blocks Th2 cytokine responses
Köpf, M., Gros, G. S. L., Bachmann, M. F., Lamers, M. C., Bluethmann, H., & Köhler, G. (1993) · Nature · doi:10.1038/362245a0 · Cited by 1,202
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 1,014

Flagged first, then by citations

Show all 63 references

Research works printed but not linked: 1

Ramon, G. Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxine diphtherique rendue anatoxique. C. R. Hebd. Seances Acad. Sci. 177, 1338–1340 (1923).

Sorted by citations

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,927
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,478
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., Arunachalam, P. S., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,446
‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants
Shoenfeld, Y., & Agmon‐Levin, N. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.07.003 · Cited by 1,017
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 757
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 770
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A. D., Preiss, S., Silva, F. T. D., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 653
Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed
Panel), E. P. O. G. M. O. (. (2010) · EFSA Journal · doi:10.2903/j.efsa.2010.1700 · Cited by 611
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 605
A self-assembling peptide acting as an immune adjuvant
Rudra, J. S., Tian, Y. F., Jung, J. P., & Collier, J. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912124107 · Cited by 523
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Pasquale, A. D., Hergli, N., Collignon, C., & Garçon, N. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 536
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts
Willhite, C. C., Karyakina, N. A., Yokel, R. A., Yenugadhati, N., Wısnıewskı, T., Arnold, I. M. F., Momoli, F., & Krewski, D. R. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2014.934439 · Cited by 430
Advances in aluminum hydroxide-based adjuvant research and its mechanism
Peng, H., Zou, Y., & Hu, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004026 · Cited by 415
New adjuvants for human vaccines
Mbow, M. L., Gregorio, E. D., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 419
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
Flach, T. L., Ng, G., Hari, A., Desrosiers, M. D., Zhang, P., Ward, S. M., Seamone, M. E., Vilaysane, A., Mucsi, A. D., Fong, Y., et al. (2011) · Nature Medicine · doi:10.1038/nm.2306 · Cited by 405
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
Desmet, C. J., & Ishii, K. J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3247 · Cited by 404
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 382
An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma
Kool, M., Willart, M. A. M., van Nimwegen, M., Bergen, I. M., Pouliot, P., Virchow, J. C., Jr., Rogers, N. C., Osorio, F., Sousa, C. R. E., Hammad, H., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.015 · Cited by 360
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response
Li, H., Li, Y., Jiao, J., & Hu, H. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.153 · Cited by 347
Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens
Watson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 339
Manganese salts function as potent adjuvants
Zhang, R., Wang, C., Guan, Y., Wei, X., Sha, M., Yi, M., Jing, M., Lv, M., Guo, W., Xu, J., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00669-w · Cited by 329
Shape and size-dependent immune response to antigen-carrying nanoparticles
Kumar, S., Anselmo, A. C., Banerjee, A., Zakrewsky, M., & Mitragotri, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.069 · Cited by 311
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
Demento, S. L., Cui, W., Criscione, J., Stern, E., Tulipan, J., Kaech, S., & Fahmy, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.041 · Cited by 287
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants
Maisonneuve, C., Bertholet, S., Philpott, D. J., & Gregorio, E. D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400478111 · Cited by 307
Metalloimmunology: The metal ion-controlled immunity
Wang, C., Zhang, R., Wei, X., Lv, M., & Jiang, Z. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.007 · Cited by 302
Adjuvants: Classification, Modus Operandi , and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 303
Unique aspects of the perinatal immune system
Zhang, X., Zhivaki, D., & Lo-Man, R. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.54 · Cited by 276
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Adjuvanted influenza vaccines
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
Xia, Y., Xie, Y., Yu, Z., Xiao, H., Jiang, G., Zhou, X., Yang, Y., Li, X., Zhao, M., Li, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.070 · Cited by 259
Physical activation of innate immunity by spiky particles
Wang, J., Chen, H., Hang, T., Yu, Y., Liu, G., He, G., Xiao, S., Yang, B., Yang, C., Liu, F., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0274-0 · Cited by 248
Antigen depot is not required for alum adjuvanticity
Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., & Brewer, J. M. (2011) · The FASEB Journal · doi:10.1096/fj.11-184556 · Cited by 241
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
Knudsen, N. P. H., Olsen, A. W., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R. N., Fox, C. B., Meinke, A. L., D’Oro, U., Casini, D., et al. (2016) · Scientific Reports · doi:10.1038/srep19570 · Cited by 234
Mechanisms of uric acid crystal‐mediated autoinflammation
Martinon, F. (2009) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00860.x · Cited by 226
Innate and adaptive immune responses to cell death
Rock, K. L., Lai, J., & Kono, H. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01040.x · Cited by 226
From discovery to licensure, the Adjuvant System story
Garçon, N., & Pasquale, A. D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1225635 · Cited by 224
The spectrum of post-vaccination inflammatory CNS demyelinating syndromes
Karussis, D. M., & Petrou, P. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.003 · Cited by 209
Silica Crystals and Aluminum Salts Regulate the Production of Prostaglandin in Macrophages via NALP3 Inflammasome-Independent Mechanisms
Kuroda, E., Ishii, K. J., Uematsu, S., Ohata, K., Coban, C., Akira, S., Aritake, K., Urade, Y., & Morimoto, Y. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.019 · Cited by 213
Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity
Caudill, C. L., Perry, J. L., Iliadis, K., Tessema, A., Lee, B. J., Mecham, B. S., Tian, S., & DeSimone, J. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102595118 · Cited by 202
Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists
Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Abraham, S., Juel, H. B., Bang, P. F., Cheeseman, H. M., Dohn, R. B., Cole, T., Kristiansen, M. P., Korsholm, K. S., Lewis, D. J. M., Olsen, A. W., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30279-8 · Cited by 197
New-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 204
Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants
Tan, K., Li, R., Huang, X., & Liu, Q. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00783 · Cited by 193
Enzyme‐Catalyzed Formation of Supramolecular Hydrogels as Promising Vaccine Adjuvants
Wang, H., Luo, Z., Wang, Y., He, T., Yang, C., Ren, C., Ma, L., Gong, C., Li, X., & Yang, Z. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201505188 · Cited by 183
Introduction to the Immune System
McComb, S., Thiriot, A., Akache, B., Krishnan, L., & Stark, F. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9597-4_1 · Cited by 186
Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope
Rudra, J. S., Mishra, S., Chong, A. S., Mitchell, R. A., Nardin, E. H., Nussenzweig, V., & Collier, J. H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.041 · Cited by 176
The immunobiology of aluminium adjuvants: how do they really work?
Exley, C., Siesjö, P., & Eriksson, H. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.12.009 · Cited by 184
Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity
Zhivaki, D., Borriello, F., Chow, O. A., Doran, B. A., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 170
Designing and building the next generation of improved vaccine adjuvants
Brito, L. A., & O’Hagan, D. T. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.027 · Cited by 164
Monosodium urate crystals in inflammation and immunity
Shi, Y., Mucsi, A. D., & Ng, G. (2009) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00851.x · Cited by 163
Tailoring inorganic nanoadjuvants towards next-generation vaccines
Li, X., Wang, X., & Ito, A. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00028j · Cited by 153
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
Wang, S., Liu, H., Zhang, X., & Qian, F. (2015) · Protein & Cell · doi:10.1007/s13238-015-0164-2 · Cited by 157
Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) – An update
Watad, ‬., Quaresma, M., Brown, S., Tervaert, J. W. C., Rodríguez‐Pintó, I., Cervera, R., Perricone, C., & Shoenfeld, Y. (2017) · Lupus · doi:10.1177/0961203316686406 · Cited by 150
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings
Xu, D.-Z., Wang, X., Shen, X., Gong, G., Ren, H., Guo, L., Sun, A.-M., Xu, M., Li, L., Guo, X., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.003 · Cited by 149
Subunit Vaccines of the Future: the Need for safe, Customized and Optimized Particulate Delivery Systems
Foged, C. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.68 · Cited by 148
Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?
Vadalà, M., Poddighe, D., Laurino, C., & Palmieri, B. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0101-y · Cited by 150
The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm
Ghimire, T. R. (2015) · SpringerPlus · doi:10.1186/s40064-015-0972-0 · Cited by 156
Liposomal vaccine delivery systems
Henriksen‐Lacey, M., Korsholm, K. S., Andersen, P. L., Perrie, Y., & Christensen, D. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.558081 · Cited by 146
Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research
Levitz, S. M., & Golenbock, D. T. (2012) · Cell · doi:10.1016/j.cell.2012.02.012 · Cited by 144
Vaccines with Aluminum-containing Adjuvants: Optimizing Vaccine Efficacy and Thermal Stability
Clapp, T., Siebert, P., Chen, D., & Braun, L. J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22284 · Cited by 138
Adjuvant formulations for virus-like particle (VLP) based vaccines
Cimica, V., & Galarza, J. M. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.004 · Cited by 140
An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy
Wang, Y., Santos, A., Evdokiou, A., & Lošić, D. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00956a · Cited by 140
Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation
Zhang, W., Wang, L., Liu, Y., Chen, X., Liu, Q., Jia, J., Yang, T., Qiu, S., & Ma, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.022 · Cited by 139
Vaccine development: From concept to early clinical testing
Cunningham, A. L., Garçon, N., Léo, O., Friedland, L. R., Strugnell, R. A., Laupèze, B., Doherty, M. T., & Stern, P. L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.016 · Cited by 151
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells
MacLeod, M. K. L., McKee, A. S., David, A. P., Wang, J., Mason, R. J., Kappler, J. W., & Marrack, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104588108 · Cited by 137
Self-citation
The Inflammasomes
Lamkanfi, M., & Dixit, V. M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000510 · Cited by 139
Vaccine responses in newborns
Saso, A., & Kampmann, B. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0654-9 · Cited by 139
ASIA syndrome and endocrine autoimmune disorders
Bragazzi, N. L., Hejly, A., Watad, ‬., Adawi, M., Amital, H., & Shoenfeld, Y. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101412 · Cited by 134
Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T. M., Tao, X., Tasneem, S., Lu, L., Tseng, C.-T. K., et al. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.03 · Cited by 128
Functionalized carbon nanotubes as immunomodulator systems
Pescatori, M., Bedognetti, D., Venturelli, E., Ménard‐Moyon, C., Bernardini, C., Muresu, E., Piana, A. F., Maida, G., Manetti, R., Sgarrella, F., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.052 · Cited by 128
The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum
Gaynor, D., & Griffith, D. M. (2012) · Dalton Transactions · doi:10.1039/c2dt31601c · Cited by 127
Innate immune detection of lipid oxidation as a threat assessment strategy
Zhivaki, D., & Kagan, J. C. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00618-8 · Cited by 129
Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells
Han, S.-W., Sun, L., He, F., & Che, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-07833-1 · Cited by 106
Immunology of TLR-independent vaccine adjuvants
Gregorio, E. D., D’Oro, U., & Wack, A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.003 · Cited by 127
Toward precision adjuvants: optimizing science and safety
Nanishi, E., Dowling, D. J., & Levy, O. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000868 · Cited by 130
Vaccine delivery carriers: Insights and future perspectives
Correia‐Pinto, J., Csaba, N., & Alonso, M. J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.047 · Cited by 122
Selection of adjuvants for vaccines targeting specific pathogens
Sarkar, I., Garg, R., & den Hurk, S. V. D. L. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1604231 · Cited by 122
Overview of Vaccine Adjuvants: Introduction, History, and Current Status
Shah, R. R., Hassett, K. J., & Brito, L. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6445-1_1 · Cited by 121
Needle-free influenza vaccination
Amorij, J., Hinrichs, W. L. J., Frijlink, H. W., Wilschut, J., & Huckriede, A. L. W. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70157-2 · Cited by 120
Influenza vaccines: Past, present, and future
Kim, Y. H., Hong, K., Kim, H., & Nam, J. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2243 · Cited by 123
Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways
Philbin, V. J., Dowling, D. J., Gallington, L. C., Cortés, G., Tan, Z. W., Suter, E. E., Chi, K. W., Shuckett, A., Stoler‐Barak, L., Tomai, M. A., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.042 · Cited by 116
A Vaccine Strategy that Induces Protective Immunity against Heroin
Stowe, G. N., Vendruscolo, L. F., Edwards, S., Schlosburg, J. E., Misra, K., Schulteis, G., Mayorov, A. V., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200461m · Cited by 116
Particulate Adjuvant and Innate Immunity: Past Achievements, Present Findings, and Future Prospects
Kuroda, E., Coban, C., & Ishii, K. J. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.773326 · Cited by 115
The Impact of Size on Particulate Vaccine Adjuvants
Shah, R. R., O’Hagan, D. T., Amiji, M. M., & Brito, L. A. (2014) · Nanomedicine · doi:10.2217/nnm.14.193 · Cited by 115
A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog
Christensen, D., Henriksen‐Lacey, M., Kamath, A. T., Lindenstrøm, T., Korsholm, K. S., Christensen, J. P., Rochat, A., Lambert, P., Andersen, P. L., Siegrist, C., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.016 · Cited by 113
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
Leroux-Roels, G. G., Marchant, A., Lévy, J., Damme, P. V., Schwarz, T. F., Horsmans, Y., Jilg, W., Kremsner, P. G., Haelterman, E., Clément, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.007 · Cited by 113
Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology
Orr, M. T., Khandhar, A. P., Seydoux, E., Liang, H., Gage, E., Mikasa, T. J. T., Beebe, E. L., Rintala, N. D., Persson, K. H., Ahniyaz, A., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0094-0 · Cited by 110
Combination adjuvants: the next generation of adjuvants?
Mutwiri, G., Gerdts, V., den Hurk, S. V. D. L., Auray, G., Eng, N. F., Garlapati, S., Babiuk, L. A., & Potter, A. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.154 · Cited by 110
Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules
Wagner, A., Garner‐Spitzer, E., Jasińska, J., Kollaritsch, H., Stiasny, K., Kundi, M., & Wiedermann, U. (2018) · Scientific Reports · doi:10.1038/s41598-018-28111-8 · Cited by 114
Current adjuvants and new perspectives in vaccine formulation
Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R., & Rosa, A. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.48 · Cited by 108
Advances in Infectious Disease Vaccine Adjuvants
Fan, J., Jin, S., Gilmartin, L., Tóth, I., Hussein, W. M., & Stephenson, R. J. (2022) · Vaccines · doi:10.3390/vaccines10071120 · Cited by 118
Th17 cell based vaccines in mucosal immunity
Kumar, P., Chen, K., & Kolls, J. K. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.011 · Cited by 105
Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21
Welsby, I., Detienne, S., N’Kuli, F., Thomas, S., Wouters, S., Bechtold, V., Wit, D. D., Gineste, R., Reinheckel, T., Elouahabi, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00663 · Cited by 105
Polymeric micro/nanoparticles: Particle design and potential vaccine delivery applications
Yue, H., & Ma, G. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.100 · Cited by 105
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
Sundling, C., Forsell, M. N. E., O'Dell, S. J., Feng, Y., Chakrabarti, B. K., Rao, S. S., Loré, K., Mascola, J. R., Wyatt, R. T., Douagi, I., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100025 · Cited by 102
Biodegradable Metal Ion-Doped Mesoporous Silica Nanospheres Stimulate Anticancer Th1 Immune Response in Vivo
Wang, X., Li, X., Ito, A., Sogo, Y., Watanabe, Y., Tsuji, N. M., & Ohno, T. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16118 · Cited by 101

Authors: Marrack, P., McKee, A. S., & Munks, M. W.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Marrack, Philippa
ORCID: Marrack, Philippa
McKee, Amy S.
Munks, Michael W.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2009-04
Volume: 9
Issue: 4
Pages: 287-293
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri2510
PMC: PMC3147301
OpenAlex: W1990954596
Cited by: 887
References: 63
Citations by year: 2026: 44 · 2025: 47 · 2024: 57 · 2023: 47 · 2022: 41 · 2021: 67 · 2020: 50 · 2019: 45 · 2018: 49 · 2017: 65 · 2016: 56 · 2015: 72 · 2014: 44 · 2013: 64 · 2012: 49
FWCI: 3.59
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Institute of Allergy and Infectious Diseases (P01AI022295, R37AI018785)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Agricultural and Biological Sciences › Plant Science › Aluminum toxicity and tolerance in plants and animals
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: alum adjuvant, aluminum salts, vaccine adjuvants, adjuvant mechanisms, vaccine efficacy, immunogenicity
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Adjuvants, Immunologic, Adsorption, Aluminum, Animals, Antibody Formation, Antigen-Presenting Cells, Antigens, Carrier Proteins, Cytoskeletal Proteins, Humans, Immunity, Cellular, Immunity, Innate, Aluminum Compounds, Models, Immunological, Caspase 1, Apoptosis Regulatory Proteins, Mice, CARD Signaling Adaptor Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Towards an understanding of the adjuvant action of aluminium

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks